UPB (Upstream Bio) Piotroski F-Score: N/A (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UPB Upstream Bio Inc UPB
10 GF Score
Price $6.99
! 1 Warning Sign
View Full Analysis

What is Upstream Bio Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Upstream Bio has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Upstream Bio's Piotroski F-Score or its related term are showing as below:

During the past 4 years, the highest Piotroski F-Score of Upstream Bio was 3. The lowest was 2. And the median was 3.

Upstream Bio  (NAS:UPB) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Upstream Bio Piotroski F-Score Related Terms


Upstream Bio Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Upstream Bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Upstream Bio Piotroski F-Score Chart

Upstream Bio Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
N/A N/A N/A 3.00

Upstream Bio Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 2.00 N/A 3.00 N/A

UPB vs OABI, VNDA, LXEO: Piotroski F-Score Comparison

For the Biotechnology subindustry, Upstream Bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Upstream Bio Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Upstream Bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Upstream Bio's Piotroski F-Score falls into.


UPB
10GF Score
Upstream Bio Inc UPB
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -39.966 + -33.748 + -42.459 + -40.591 = $-156.76 Mil.
Cash Flow from Operations was -39.239 + -22.24 + -30.631 + -47.852 = $-139.96 Mil.
Revenue was 0.937 + 0.683 + 0.668 + 1.034 = $3.32 Mil.
Gross Profit was 0.937 + 0.683 + 0.668 + 1.034 = $3.32 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(456.169 + 420.521 + 391.195 + 353.772 + 318.054) / 5 = $387.9422 Mil.
Total Assets at the begining of this year (Mar25) was $456.17 Mil.
Long-Term Debt & Capital Lease Obligation was $0.39 Mil.
Total Current Assets was $316.28 Mil.
Total Current Liabilities was $13.67 Mil.
Net Income was -14.678 + -15.992 + -21.242 + -27.27 = $-79.18 Mil.

Revenue was 0.51 + 0.607 + 0.613 + 0.566 = $2.30 Mil.
Gross Profit was 0.51 + 0.607 + 0.613 + 0.566 = $2.30 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(0 + 244.511 + 232.7 + 481.719 + 456.169) / 5 = $353.77475 Mil.
Total Assets at the begining of last year (Mar24) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $0.99 Mil.
Total Current Assets was $453.79 Mil.
Total Current Liabilities was $9.57 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Upstream Bio's current Net Income (TTM) was -156.76. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Upstream Bio's current Cash Flow from Operations (TTM) was -139.96. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-156.764/456.169
=-0.34365334

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-79.182/0
=

Upstream Bio's return on assets of this year was -0.34365334. Upstream Bio's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Upstream Bio's current Net Income (TTM) was -156.76. Upstream Bio's current Cash Flow from Operations (TTM) was -139.96. ==> -139.96 > -156.76 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0.39/387.9422
=0.0010053

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0.992/353.77475
=0.00280404

Upstream Bio's gearing of this year was 0.0010053. Upstream Bio's gearing of last year was 0.00280404. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=316.279/13.669
=23.13841539

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=453.787/9.567
=47.43252848

Upstream Bio's current ratio of this year was 23.13841539. Upstream Bio's current ratio of last year was 47.43252848. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Upstream Bio's number of shares in issue this year was 54.332. Upstream Bio's number of shares in issue last year was 53.618. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3.322/3.322
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2.296/2.296
=1

Upstream Bio's gross margin of this year was 1. Upstream Bio's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=3.322/456.169
=0.00728239

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=2.296/0
=

Upstream Bio's asset turnover of this year was 0.00728239. Upstream Bio's asset turnover of last year was . ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Upstream Bio has an F-score of 4 indicating the company's financial situation is typical for a stable company.


Upstream Bio Business Description

Address 890 Winter Street, Suite 200, Waltham, MA, USA, 02451
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
10GF Score

Get the complete analysis for UPB

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.99
Price